Enristas 2MF Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, which aids in lowering blood glucose levels without causing significant hypoglycemia. The combination of these two agents provides complementary mechanisms of action, offering effective glycemic management in patients inadequately controlled on monotherapy. Enristas 2MF Tablet PR is indicated for adult patients with type 2 diabetes who require dual therapy to achieve target blood glucose levels, particularly when diet and exercise alone are insufficient. The prolonged-release formulation allows for sustained drug release, promoting better adherence through reduced dosing frequency and minimizing gastrointestinal side effects commonly associated with Metformin. This medication should be used under medical supervision, with regular monitoring of blood glucose, renal function, and potential adverse effects such as hypoglycemia, lactic acidosis, or gastrointestinal disturbances. Dose adjustments may be necessary based on patient response and tolerability.